Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy
Status:
Recruiting
Trial end date:
2021-12-27
Target enrollment:
Participant gender:
Summary
The positive cases of coronavirus disease-2019 (COVID-19) in Indonesia has been increasing
rapidly since the first case found in March 2020 to date. Coronavirus 2 (SARS-CoV-2) virus
disrupts human normal immune system resulting in uncontrolled inflammatory response. Based on
our research and experience in doing cell therapy for 9 years, activated platelet-rich plasma
(PRP) produces anti-inflammatory effects in inflammatory condition that is beneficial for
tissue regeneration. In this study, we aimed to evaluate the potential of autologous
activated platelet-rich plasma (aaPRP) and the outcomes for treating severe Coronavirus
Disease-2019 (COVID-19) patients in Intensive Care Unit (ICU).